The CAPSTONE study is the largest ever comparative utility study in lupus diagnostics. But why was the study necessary to conduct? What did the process look like? And what do the results prove? Answering these questions are our two interviewees: Dr. Debra Zack, Chief Medical Officer for Exagen and Tyler O’Malley, Director of Evidence Development for Exagen and co-author of the study. Join them on this four-part journey as they explore the unmet need that prompted the study, the conclusive results from the study, and what these discoveries mean for both patients and providers.
As a patient focused, discovery driven company, Exagen’s AVISE tests are built on a robust foundation of evidence. The Exagen Evidence Journey Podcast Series explores research, conclusive results, and findings from studies using AVISE testing.
